Evaluation of the Added Value of a Large Molecular Profiling Panel Versus a Limited Molecular Profiling Panel in Advanced Solid Tumors.

NACompletedINTERVENTIONAL
Enrollment

341

Participants

Timeline

Start Date

June 29, 2017

Primary Completion Date

November 23, 2021

Study Completion Date

November 23, 2021

Conditions
Advanced Solid Tumor
Interventions
GENETIC

Blood and tumor samples

Evaluation of the added value of a large molecular profiling panel versus a limited molecular profiling panel

Trial Locations (15)

13273

Institut Paoli Calmettes, Marseille

13915

AP-HM MARSEILLE - Hôpital Nord, Marseille

31059

Institut Claudius Regaud, Toulouse

33076

Institut Bergonié, Bordeaux

44805

ICO site René Gauducheau, Saint-Herblain

69008

Centre Léon Bérard, Lyon

75231

Institut Curie, Paris

75970

Hopital Tenon, Paris

422270

Institut de Cancérologie Lucien NEUWIRTH, Saint-Priest-en-Jarez

Unknown

Centre Jean PERRIN, Clermont-Ferrand

Centre Georges François LECLERC, Dijon

Centre Oscar Lambret, Lille

Hôpital Privé Jean Mermoz, Lyon

Institut cancer Montpellier - ICM, Montpellier

Centre Eugène Marquis, Rennes

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Centre Leon Berard

OTHER

NCT03163732 - Evaluation of the Added Value of a Large Molecular Profiling Panel Versus a Limited Molecular Profiling Panel in Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter